IN HONOR OF NATIONAL PIE DAY AWARD-WINNING BAKER, COOKBOOK AUTHOR AND BLOGGER ROSE LEVY BERANBAUM JOINS THE SHOW
Rose's new product line, "Rose Levy Beranbaum Signature Series" by American Products Group, was launched in 2015 and is available on Amazon along with her All-Original All-American Pie Recipes E-Booklet. Her upcoming book: "Rose's Baking Basics," Fall 2018, will offer over 600 step by step photos.
Rose's All-Original All-American Pie Recipes
Rose's Baking Basics is now available on pre-sale!
LEADING EXPERT ON DEPRESSION AND MENTAL HEALTH DISORDERS DR. SAGAR V. PARIKH, M.D. - SEVERE WINTER DEPRESSION - GENETIC TESTING HELPS PATIENTS GET THE RIGHT TREATMENT
Genetic Testing Helps Patients Get the Right Treatment Based on Their Genetic Profile
Many of the 19 million people who suffer from depression “year round” often get worse in the winter months. Additionally, approximately 11 million Americans suffer from a severe winter form of major depression called Seasonal Affective Disorder (SAD).
Many factors, including financial debt, too many commitments, weight gain, bad weather and broken resolutions all can cause depression in the post-holiday winter months or cause existing depression to worsen.
Sufferers may exhibit symptoms, such as feelings of hopelessness and worthlessness, thoughts of suicide, loss of interest in activities, withdrawal from social interaction, sleep and appetite problems, difficulty with concentrating and making decisions, decreased sex drive, a lack of energy, or agitation.
An important clinical study published in the Molecular Neuropsychiatry Journal, showed that patients whose treatment was guided by the GeneSight test experienced 70% greater improvement in depressive symptoms versus treatment as usual.
Medicare and other health plans cover the GeneSight test for patients who have failed one or more anti-depressant medications. So far, more than 23,000 healthcare professionals have used GeneSight with more than 650,000 of their patients.
ABOUT THE GENESIGHT® TEST
GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, manufacturers’ FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient. For more information about GeneSight, please visit www.genesight.com.